Claudia Muscarà

Dr. Claudia Muscarà

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Antonio SpecialeAntonio Speciale
Antonio Speciale
CMClaudia Muscarà
Claudia Muscarà
MMMaria Sofia Molonia
Maria Sofia Molonia
CMCristani Mariateresa
Cristani Mariateresa
Francesco CiminoFrancesco Cimino
Francesco Cimino
Antonina SaijaAntonina Saija
Antonina Saija
Liver cancer is one of the most common causes of cancer mortality worldwide. Chemotherapy and radiotherapy are the conventional therapies generally employed in patients with liver tumors. The major issue associated with the administration of chemotherapeutics is their high toxicity and lack of selectivity, leading to systemic toxicity that can be detrimental to the patient’s quality of life. An important approach to the development of original liver-targeted therapeutic products takes advantage of the employment of biologically active ligands able to bind specific receptors on the cytoplasmatic membranes of liver cells. In this perspective, glycyrrhetinic acid (GA), a pentacyclic triterpenoid present in roots and rhizomes of licorice, has been used as a ligand for targeting the liver due to the expression of GA receptors on the sinusoidal surface of mammalian hepatocytes, so it may be employed to modify drug delivery systems (DDSs) and obtain better liver or hepatocyte drug uptake and efficacy. In the current review, we focus on the most recent and interesting research advances in the development of GA-based hybrid compounds and DDSs developed for potential employment as efficacious therapeutic options for the treatment of hepatic cancer.

1 March 2019 in Phytomedicine
Verified
Journal Article
Closed access
Deborah FratantonioDeborah Fratantonio
Deborah Fratantonio
MMMaria Sofia Molonia
Maria Sofia Molonia
RBRomina Bashllari
Romina Bashllari
CMClaudia Muscarà
Claudia Muscarà
GFGuido Ferlazzo
Guido Ferlazzo
Antonio SpecialeAntonio Speciale
Antonio Speciale

6 April 2021 in Phytotherapy Research
Verified
Journal Article
Open access
PDF file
Antonio SpecialeAntonio Speciale
Antonio Speciale
CMClaudia Muscarà
Claudia Muscarà
MMMaria Sofia Molonia
Maria Sofia Molonia
Francesco CiminoFrancesco Cimino
Francesco Cimino
Antonina SaijaAntonina Saija
Antonina Saija
Salvatore GiofrèSalvatore Giofrè
Salvatore Giofrè
The spread of SARS‐CoV‐2, along with the lack of targeted medicaments, encouraged research of existing drugs for repurposing. The rapid response to SARS‐CoV‐2 infection comprises a complex interaction of cytokine storm, endothelial dysfunction, inflammation, and pathologic coagulation. Thus, active molecules targeting multiple steps in SARS‐CoV‐2 lifecycle are highly wanted. Herein we explored the in silico capability of silibinin from Silybum marianum to interact with the SARS‐CoV‐2 main target proteins, and the in vitro effects against cytokine‐induced‐inflammation and dysfunction in human umbilical vein endothelial cells (HUVECs). Computational analysis revealed that silibinin forms a stable complex with SARS‐CoV‐2 spike protein RBD, has good negative binding affinity with Mpro, and interacts with many residues on the active site of Mpro, thus supporting its potentiality in inhibiting viral entry and replication. Moreover, HUVECs pretreatment with silibinin reduced TNF‐α‐induced gene expression of the proinflammatory genes IL‐6 and MCP‐1, as well as of PAI‐1, a critical factor in coagulopathy and thrombosis, and of ET‐1, a peptide involved in hemostatic vasoconstriction. Then, due to endothelium antiinflammatory and anticoagulant properties of silibinin and its capability to interact with SARS‐CoV‐2 main target proteins demonstrated herein, silibinin could be a strong candidate for COVID‐19 management from a multitarget perspective.

9 October 2020 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
CMClaudia Muscarà
Claudia Muscarà
Antonella SmeriglioAntonella Smeriglio
Antonella Smeriglio
Domenico TrombettaDomenico Trombetta
Domenico Trombetta
Giuseppina MandalariGiuseppina Mandalari
Giuseppina Mandalari
ECErminia La Camera
Erminia La Camera
CCClara Circosta
Clara Circosta

6 October 2020 in Archives of Physiology and Biochemistry
Verified
Journal Article
Closed access
RBRomina Bashllari
Romina Bashllari
MMMaria Sofia Molonia
Maria Sofia Molonia
CMClaudia Muscarà
Claudia Muscarà
Antonio SpecialeAntonio Speciale
Antonio Speciale
Peter WildePeter Wilde
Peter Wilde
Francesco CiminoFrancesco Cimino
Francesco Cimino
Increased free fatty acids (FFAs) levels, typical in obesity condition, can contribute to systemic lipotoxicity and inflammation adversely influencing Inflammatory Bowel Disease development and pro...

23 April 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Antonio SpecialeAntonio Speciale
Antonio Speciale
ASAntonella Saija
Antonella Saija
RBRomina Bashllari
Romina Bashllari
MMMaria Sofia Molonia
Maria Sofia Molonia
CMClaudia Muscarà
Claudia Muscarà
MCMariateresa Cristani
Mariateresa Cristani
: Chronic Noncommunicable Diseases (NCDs), mostly represented by cardiovascular diseases, diabetes, chronic pulmonary diseases, cancers, and several chronic pathologies, are one of the main causes of morbidity and mortality, and are mainly related to the occurrence of metabolic risk factors. Anthocyanins (ACNs) possess a wide spectrum of biological activities, such as anti-inflammatory, antioxidant, cardioprotective and chemopreventive properties, which are able to promote human health. Although ACNs present an apparent low bioavailability, their metabolites may play an important role in the in vivo protective effects observed. : This article directly addresses the scientific evidences supporting that ACNs could be useful to protect human population against several NCDs not only acting as antioxidant but through their capability to modulate cell redox-dependent signaling. In particular, ACNs interact with the NF-κB and AP-1 signal transduction pathways, which respond to oxidative signals and mediate a proinflammatory effect, and the Nrf2/ARE pathway and its regulated cytoprotective proteins (GST, NQO, HO-1, etc.), involved in both cellular antioxidant defenses and elimination/inactivation of toxic compounds, so countering the alterations caused by conditions of chemical/oxidative stress. In addition, supposed crosstalks could contribute to explain the protective effects of ACNs in different pathological conditions characterized by an altered balance among these pathways. Thus, this review underlines the importance of specific nutritional molecules for human health and focuses on the molecular targets and the underlying mechanisms of ACNs against various diseases.